Fairvalue-Calculator Fairvalue-Calculator
EN DE

ALOPM (ALOPM) Fair Value & Analysis

Healthcare · FR · Market cap €7.6M

Price€0.3420
Fair Value€0.3365
Upside-1.6%
Quality89/100
Evidence: Medium Range €0.2524 – €0.4206

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ALOPM (ALOPM) currently trades at €0.3420, while our model-based Fair Value estimate is €0.3365 — implying the stock looks roughly 1.6% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is ALOPM (ALOPM) undervalued?
As of Jun 25, 2026, our model estimates a fair value of €0.3365 versus a price of €0.3420 — about −2% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALOPM?
Our 21-model fair value for ALOPM is €0.3365 (as of Jun 25, 2026), built from audited fundamentals. The current price is €0.3420.
What is the quality score of ALOPM?
ALOPM has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.